Kalaris Therapeutics, Inc. Common Stock KLRS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -66.6%— | —— | —— | —— | —— | |
| Return on assets | -41.4%+20.0pp | -67.9%+2.3pp | -54.5%— | -73%-18.3pp | -61.4%+17.2pp | |
| Liquidity | ||||||
| Current ratio | 12.2×-2.1× | 12.2×+12.1× | 12.9×-73.9× | 12×-43.1× | 14.3×-4.2× | |
| Quick ratio | 12.2×-2.1× | 12.2×+12.1× | 12.9×-73.9× | 12×-43.1× | 14.3×-4.2× | |
| Cash ratio | 4.3×-9.9× | 10.1×+10.0× | 7×+5.6× | 11.6×+8.9× | 14.1×+13.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×— | 0×— | 0×— | —— | —— | |
| Debt-to-assets | 0×— | 0×— | 0×— | —— | —— | |
| Per Share | ||||||
| Book value per share | $2.89-81.7% | $5.16+107% | $2.24+103% | $2.84+107% | $15.76+144% | |
| Valuation | ||||||
| Market capitalization | $96.83M+136% | $157.85M— | $108.1M— | $46.57M— | —— | |
| Enterprise value | $63.82M— | $61.24M— | $67.26M— | —— | —— | |
| Price / book | 1.6×+0.7× | 2×— | 2.6×— | 0.9×— | —— | |
| Earnings yield | -39%+132pp | -27.5%— | -51.3%— | -175.3%— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kalaris Therapeutics, Inc. Common Stock's ratios come from?
- Every ratio is computed from Kalaris Therapeutics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.